|Bid||100.00 x 1000|
|Ask||130.91 x 1800|
|Day's Range||129.45 - 131.18|
|52 Week Range||118.62 - 148.99|
|Beta (3Y Monthly)||0.62|
|PE Ratio (TTM)||229.68|
|Earnings Date||Jan 22, 2019|
|Forward Dividend & Yield||3.60 (2.79%)|
|1y Target Est||145.50|
Global stocks retreat for a second day on twin concerns for word economic growth in the form of a sharp China slowdown and reduced 2019 forecasts from the IMF. European stocks clipped by growth concerns and Brexit uncertainty as Prime Minister Theresa may attempts to revive her rejected exit deal. U.S. equity futures suggest a 17 point pullback for the S&P 500 and a 150-point slide for the Dow at start of trading.
AbbVie's (ABBV) Imbruvica falls short of meeting the primary endpoint of PFS or OS benefit in a phase III study that probed its combo usage in first-line metastatic pancreatic cancer.
Put Up or Shut Up Time for the Stock Market After the RallyWhat a rally After a furious Christmas eve to a now month-long rally, the stock market must now decide what to do: break up through the downtrend or test the lows and make this look like a
By Arno Schuetze, Pamela Barbaglia and Martinne Geller FRANKFURT/LONDON (Reuters) - Private equity firms Cinven and Advent have teamed up to bid in an auction that could value Nestle's (NESN.S) skin health ...
Numbers from Halliburton, IBM, Johnson & Johnson, Stanley Black & Decker and Travelers could tell us where stocks go from here.
What about all of the intelligentsia that come on air and tell us that the Chinese are playing the long game and we'll lose in the end? Well, I think they aren't businesspeople. What's really amazing is how universally contemptuous businesspeople are of the Chinese.
NEW ORLEANS , Jan. 18, 2019 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF ...
Twelve weeks a year, investors need to be on the top of their game, Jim Cramer told his Mad Money viewers Friday. Cramer remained a fan of the deal. Cramer was a fan of Comcast's bid to buy Sky, and also liked the outlooks for both Procter and the very consistent Abbott Labs.
CNBC's Jim Cramer looks ahead at a busy week of earnings reports that he says might drive investors crazy. Johnson & Johnson, Comcast and Starbucks will be among the companies issuing quarterly results. "I can't recall a time when the forecast will be more important, certainly much more important than the results," Cramer, host of "Mad Money," told viewers.
AbbVie Inc said on Friday its blockbuster cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer. The treatment, Imbruvica, failed to show statistically significant improvement in progression-free survival (PFS) or overall survival in metastatic pancreatic cancer patients, compared with the combination of placebo and two chemotherapy agents. The American Cancer society estimates that pancreatic cancer accounts for about 3 percent of all cancers in the United States and about 7 percent of all cancer deaths, and expects that 56,770 people will be diagnosed with pancreatic cancer in 2019.
The major benchmarks made gains, but Netflix fell despite reporting a strong quarter. Elsewhere, Apple and Johnson & Johnson announced a new collaboration.
Apple (AAPL) partners with Johnson & Johnson to conduct multi-year research study for early detection of irregular heart conditions.
Shares of Johnson & Johnson (NYSE:JNJ) have not been trading well, unlike the rest of the market. In fact, the JNJ has moved in the exact opposite direction as the market has over the past few several months. While the rest of U.S. stock market was taking a beating in October and November, Johnson & Johnson stock was one of a handful of names that kept on grinding higher. Of course, it helps that JNJ is a well-known blue-chip dividend stock that investors flock to for safety during bouts of volatility. In December though, investors dumped the stock after negative reports about JNJ surfaced. They allege that Johnson & Johnson failed to alert authorities that at times some of its baby powder products contained asbestos, something the company knew for decades. That's a pretty bold allegation, particularly given the vulnerability of its customer. In any regard, J&J was quick to come out in its own defense and even issued a $5 billion buyback plan. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Even sector M&A -- highlighted by Bristol-Myers' (NYSE:BMY) massive $74 billion deal for Celgene (NASDAQ:CELG) -- wasn't enough to give JNJ much of a lift. Although, the price has stabilized. ### Will It Impact Earnings? The question is, will this report impact the company's fiscal fourth-quarter earnings results, which will be released before the open on Tuesday January 22nd? * 7 Companies Apple Should Consider Buying I imagine that management will address the issue from a proactive position during the company's conference call. I expect them to deny these claims and let their legal team do the heavy lifting. All management is looking to do is reassure investors that the company is not in the wrong -- not that it will be the first time it has faced a major issue though. From a quarterly perspective, it doesn't really matter. JNJ is all about building long-term moats and maintaining its place among the healthcare sector. This situation is unlikely to dethrone the company, even if it does cause some short-term waves in the stock price. Remember, many investors are in this for the long term. As it stands, analysts expect $1.95 in earnings per share for the fourth quarter, representing 12.1% growth year-over-year (YoY). That's impressive growth considering that revenue estimates actually call for a 0.1% contraction to $20.17 billion. Also worth pointing out is that earnings estimates haven't really budged even amid these baby powder reports. 30 days and 60 days ago, analysts were looking for $1.95 in earnings per share and 90 days ago they were looking for $1.96 in EPS. Current estimates call for earnings growth of 11.8% this year to $8.16 per share. However, 2019 estimates call for growth of just 5.5% to $8.61 per share. Revenue growth is expected to fall from 6.4% in 2018 to just 1.6% in 2019. In this respect, let's see where management's guidance falls and whether its better or worse than consensus expectations. ### Trading JNJ Stock So what clues do we see from JNJ stock price ahead of earnings? Shares have been consolidating nicely near $128 to $129 per share. It's a surprisingly tight coil for a stock that's been so quickly beaten down. Investors likely felt that $122 was too much of a selloff, but aren't willing to bid the name up too much ahead of an event like earnings and after a damning baby powder report. It's encouraging to see that the declining 21-day moving average did not weigh on the stock price and push it lower. Instead, JNJ stock traded right past it, like it wasn't even there. However, the stock isn't showing any willingness to trade through the 200-day moving average and ~$132 level. Investors who love JNJ for the long-term can justify adding to their position here, some $20 off the highs we saw in December. However, they should also realize that a decline down to the December lows is possible should JNJ disappoint investors next week. Also keep in mind that the market has rallied like mad over the last three weeks. A pause or decline could weigh on JNJ stock, which has largely sat out the rally this month. * 7 Retail Stocks to Buy for the Rise of Menswear From a trading perspective, I would use a close below $128 as my stop-loss. However, because earnings are involved, it's very possible that whatever direction JNJ trades in could be a gap move. On the downside, look to see if its December lows near $122 hold as support. If it can clear and close above $132, bulls may consider buying a Johnson & Johnson stock breakout. Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Companies Apple Should Consider Buying * 7 Beaten-Up Housing Stocks Due for a Bounce Back * Take Buffett's Advice: 5 Vanguard Funds to Buy Compare Brokers The post Should You Load Up on JNJ Stock Before Earnings? appeared first on InvestorPlace.
Editor's note: InvestorPlace's Earnings Reports to Watch is updated weekly. Please check back next week for our latest earnings picks. Earnings season is here. And it certainly seems like a big one. The market has rallied in 2019, with the S&P 500 already up 5%+ so far this year. So far, the earnings calendar has been favorable: financials have been the year's top stocks after solid reports from the likes of Bank of America (NYSE:BAC) and Goldman Sachs (NYSE:GS) last week. Already, it's a notable change from the earnings calendar in late October and early November when even strong reports seemed to be greeted with almost indiscriminate selling. Investors simply seemed too focused on forward-looking worries about trade wars, interest rates and tariffs to be optimistic about backward-looking earnings reports. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Early indications suggest that has changed. That, in turn, sets up some optimism toward the next few weeks, when many of the market's top stocks -- and largest companies -- report. For all the noise in the market over the past few months, corporate earnings still look strong. That suggests that the earnings calendar this time around could drive a further rebound in the broad market. But for that to be the case, earnings have to cooperate. And earnings reports next week should show whether that will be the case. Several Dow Jones Industrial Average components report, but these three look like the most important. One of the market's most widely-owned stocks will try and bounce back from a big decline. A consumer giant will try and prove that there's value in a sector that has struggled of late. And a chip giant will try and keep the bounce in that sector going. * 7 Retail Stocks to Buy for the Rise of Menswear It's a big week for the market -- one that could determine how U.S. stocks trade for the rest of 2019. ### Johnson & Johnson (JNJ) Source: Shutterstock Earnings Report Date: Tuesday, Jan. 22, before market open Johnson & Johnson (NYSE:JNJ) has a key earnings report on Tuesday, but the numbers might not be the focus. JNJ stock still hasn't recovered from a 10% decline last month, when a Reuters report claimed the company covered up the asbestos in its baby powder. JNJ's market capitalization fell a stunning $40 billion in a single day -- and the stock still hasn't recovered. Even after the declines, JNJ still has the eighth-largest market capitalization among U.S. stocks. So the response to Tuesday's report - and management commentary about the company's legal exposure - will move the entire market, not just JNJ. The question is whether Johnson & Johnson, given multiple pending lawsuits, will even address the issue beyond a statement released at the time. Any response from the company likely will overshadow the numbers. But the lack of a response might do the same. ### Procter & Gamble (PG) Source: Mike Mozart via Flickr (Modified) Earnings Report Date: Wednesday, Jan. 23, before market open Consumer packaged goods stocks have struggled of late, as margin pressures at supermarket customers and growing private-label penetration have led revenue and earnings growth to slow. But Procter & Gamble (NYSE:PG) has been bucking the trend. PG stock bounced 35% from May lows to December highs, making it one of the top stocks in the consumer space. But PG stock has pulled back, setting up an important fiscal Q2 report on Wednesday. I've long been a skeptic toward P&G, and the recent run looks like too much. Growth remains modest at best, and the company's multiple cost-cutting efforts this decade have wrung out every dollar of expense. * 7 Companies Apple Should Consider Buying PG still looks dangerous at these levels -- and any weakness in Q2 earnings could send the stock tumbling. The gains from May lows have moved expectations higher. It remains to be seen whether P&G can meet those expectations. ### Intel (INTC) Source: Shutterstock Earnings Report Date: Thursday, Jan. 24, after market close Semiconductor stocks have benefited from the recent broad market rebound. The iShares PHLX Semiconductor ETF (NASDAQ:SOXX) has bounced about 12% off its December lows. So has chip giant Intel (NASDAQ:INTC). For those gains to continue -- for both the sector and INTC stock - Intel earnings on Thursday afternoon need to be solid. Expectations are reasonably high, with the Street looking for 11%+ revenue growth and a 13% increase in earnings per share. Given that Intel hasn't missed consensus since Q1 2017, history suggests Intel should be able to deliver at least that type of growth. If it does, that could be good news not only for INTC, but struggling chip plays like Nvidia (NASDAQ:NVDA) and rival Advanced Micro Devices (NASDAQ:AMD). Investors clearly are worried about a cyclical downturn in the sector. Intel can assuage those fears -- and send the entire sector higher with a good report. I still think those rivals are the top stocks to play a rebound in semiconductor stocks. But a strong earnings report from Intel might change my mind - and drive the entire chip space higher. As of this writing, Vince Martin did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Companies Apple Should Consider Buying * 7 Beaten-Up Housing Stocks Due for a Bounce Back * Take Buffett's Advice: 5 Vanguard Funds to Buy Compare Brokers The post 3 Earnings Reports to Watch Next Week appeared first on InvestorPlace.
Walmart, CVS, American Express, Apple, Johnson & Johnson, Rio Tinto and Tribune Publishing are the companies to watch.